It follows the acquisitions of American inhaled drug specialist OtiTopic in August, followed by Danish pharmaceutical and well-being products manufacturer Fertin Pharma in September.
These developments better position PMI to create growth opportunities in adjacent business areas that go beyond tobacco and nicotine. Indeed, PMI's 2025 goal is for at least
Vectura to play a critical role in PMI's quest for 'better'
PMI has reached an important milestone in its proposed acquisition of Vectura-a provider of innovative inhaled drug delivery solutions that enables its partners to deliver their medicines to patients.
Additionally, PMI has received confirmation that all other conditions to the offer have been satisfied or waived. The company has extended the offer to allow for the tender of further shares.
Speaking about the proposed acquisition,
'We look forward to working with Vectura's scientists and providing them with the resources and expertise to grow their business to help us achieve our goal of generating at least
Fertin Pharma and PMI: Visions aligned
This was a historic moment in the company's transformation, and a significant step on its journey toward helping create a better future for all of society.
'As we build our pipeline of smoke-free products with the goal of phasing out cigarettes and expand our business for the long-term toward areas outside of tobacco and nicotine, such as selfcare wellness, we welcome the contributions that Fertin Pharma, its management, and its employees will bring to PMI,' Olczak commented.
'PMI's future is centered on health, science, technology, and sustainable business practices to deliver innovative products and solutions that aim to improve people's lives and create a net positive impact on society.
'The world-class expertise of Fertin aligns perfectly with this vision and will be an important part of our future.'
With Fertin Pharma's substantial expertise, PMI plans to accelerate its presence in the fast-growing modern oral category via a broad range of smoke-free products. This includes nicotine pouches that can help more adults who would otherwise continue to smoke switch to better alternatives and stop smoking.
A leading developer and manufacturer of innovative pharmaceutical and well-being products based on oral and intra-oral delivery systems, Fertin Pharma is 'excited to join PMI and start this new chapter,' according to its Chief Executive Officer,
'By becoming part of PMI's transformation,' Halling added, 'Fertin will be uniquely positioned to continue to innovate, grow, and serve our customers as a leading CDMO [contract development and manufacturing company]-delivering on our vision to enable people to live healthier lives.
'Our shared commitment to science and consumer-centric innovations forms a strong basis for a very successful future together.'
OtiTopic: Growing PMI's 'Beyond Nicotine' pipeline
'The acquisition of OtiTopic is an exciting step in PMI's 'Beyond Nicotine' ambitions,' Olczak commented. 'We have world-class expertise in the research, development, and commercialization of aerosolization and inhalable devices to help speed the delivery of this exciting product to market.'
Acquisitions demonstrate PMI's ambition
Working with these three pharmaceutical companies will help drive PMI's 'Beyond Nicotine' strategy-as included in its 2020 Integrated Report-and accelerate its evolution outside of tobacco and nicotine into a broader lifestyle and consumer wellness company.
With the collective expertise represented by Vectura, Fertin Pharma, and OtiTopic, along with the existing scientific capabilities PMI has developed throughout its smoke-free transformation, these developments better position PMI to reach this ambition, create value in the long-term, and help to deliver a better, more sustainable future.
Telephone: +41 58 242 00 00
(C) 2021 Electronic News Publishing, source